REFERENCES
- Coughlin SR, Mawdsley L, et al., Obstructive sleep apnoea is in-dependently associated with an increased prevalence of meta-bolic syndrome. European HeartJournal 2004, 25(9):735–741.
- Executive Summary of the Third Report of the National Cho-lesterol Education Program (NCEP) Expert Panel on Detec-tion, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA, 2001;285:2486–2497.
- Harsch IA, Hahn EG, et al. Insulin resistance and other meta-bolic aspects of the Obstructive Sleep Apnea Syndrome. Med Sci Monit, 2005; 11(3): RA70–5.
- Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am. 2004; 88: 63–82.
- Rett K. The relation between insulin resistance and cardiovas-cular complications of the insulin resistance syndrome. Diabe-tes Obes Metab. 1999;1 (Su ppl.1): 58–16.
- Stoohs RA, Facchini F, Guilleminault C. Insulin Resistance and Sleep Disordered Breathing in Healthy Humans. Am J Respir Crit Care Med, 1996; 154: 170–174.
- Mary S. M. IP, Bing Lam, et al. Obstructive Sleep Apnea Is Inde-pendently Associated with Insulin Resista nce. Am. J. Respir. Crit. Care Med., Volume 165, Number 5, March 2002,670–676.
- Coy TV, Dimsdale JE, Ancoli IS, Clausen J. Sleep apnoea and sympathetic nervous system activity: a review. J Sleep Res 1996; 5:42–50.
- Davidson M. Clinical implications of insulin resistance syn-dromes. Am. J. Med. 1995; 99(4): 420–426.
- Peppard P, Young T, Pada M et al. Prospective study of the as-sociation between sleep-disorder breathing and hypertension. N. Engl.'. Med.; 342(19): 1378–1384
- Morse SA, Zhang R, Thakur V, Reisin E. Hypertension and the metabolic syndrome. Am] Med Sci. 2005 Dec; 330(6): 303–10.
- Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J. 2000 Jul; 16(1): 128–33.
- Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci. 2005 Dec; 330(6): 295–302.
- Grimm W, Becker HF. Obesity, sleep apnea syndrome, and rhythmogenic risk. Herz. 2006 May; 31(3):213–8; quiz 219.
- Nesto RW. Obesity: a major component of the metabolic syn-drome. Tex Heart lnst J. 2005; 32(3): 387–9.
- Kato M, Roberts Thomson P, Philips BG, et al. Impairment of endothelium-dependent vasodilatation of resistance vessels in patients whit obstructive sleep apnea. Circulation. 2000;102: 2607–2610.
- Gustiene O, Slapikas R, Marcinkeviciene J, et al. Relationship between the metabolic syndrome, endothelial function and intima-media thickness in asymptomatic middle-aged indi-viduals. Medicina (Kaunas). 2005; 41(10): 825–36.
- Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med. 2006; 38(1): 64–80.
- Geiser T, Buck F, Meyer BJ et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration. 2002; 69(3):229–34.
- Nieuwdorp M, Stroes ES, Meijers JC et all. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 2005 Apr; 5(2): 155–9
- Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a mani-festation of the metabolic syndrome. Sleep Med Rev. 2005 Jun; 9(3): 211–24.
- Mc Nicholas WT. Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome. Am] Physiol Regul lntegr Comp Physiol. 2007 ;293(4):R1666–70.
- Doherty LS, Kiely JL, Swan V et al. Long-term effects of na-sal continuous positive airway pressure therapy on cardio-vascular outcomes in sleep apnea syndrome. Chest. 2005 Jun;127(6):2076–84.
- Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardio-vascular Disease 2007; 1; 7.. Review
- Sowers J.R. et al. Role of insulin resistance and hyperinsuline-mia in development of hypertension and atherosclerosis. Lab Clin Med, 2004; 123: 647–652.
- Sowers J.R. Insulin resistance and hypertension. Am] Physiol Heart Circ Physio1. 2004; 286:H1597–1602.
- Sowers J.R., Frohlich E.D. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am, 2004; 88:63–82.
- Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hy-pertension, 1992; 19:403–418.
- Banerji MA, et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM sub-jects. Am J Physiol, 1997; 273: E425–432.
- McFarlane SI, et al. Insulin resistance and cardiovascular dis-ease. ] Clin Endocrinol Metab, 2001; 86: 713–718.
- Lakka T, Laaksonen D, Lakka H et al. Sedentary lifestyle, poor cardio respiratory fitness, and the metabolic syndrome. Med Sci. Sports Exerc. 2003;35 (8): 1279–1286.
- Katzmarzyk P, Leon A, Wilmore J et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci. Sports Exerc. 2003;35(10):1703–1709.
- lp M, Lam B, NgM et al. Obstructive sleep apnoea is indepen-dently associated with insulin resistance. Am. J. Respir. Crit. Care Med. 2002; 165: 670–676 .
- Narimiya M, Yamada H, Matsuba I et all. The effect of hypoxia on insulin and glucagon secretion in the perfused pancreas of the rat. Endocrinology. 1982;111:1010-1014.
- Cheng N, Cai W, Jiang M, Wu S. Effect of hypoxia on blood glu-cose, hormones, and insulin receptor functions in newborn calves. Pediatr Res. 1997;41:852–856.
- Despres, J.P. et al. Hyperinsulinemia as an independent risk fac-tor for ischemic heart disease. N Engl J Med.1996; 334: 952–957.
- Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord. 2004; 28 Su ppl 4: S22–28.
- Harsch IA, Schahin SP, Radespiel-Troger M et al. CPAP treatment rapidly improves insulin sensitivity in patients with OSAS. Am. J. Respir. Crit. Care Med. 2004 Jan; 169(2): 156–6